Acamprosate as First‑Line Treatment for Alcohol Craving

1. Evidence Base for Acamprosate

Acamprosate is the only pharmacologic intervention with high‑quality evidence demonstrating both effectiveness in maintaining abstinence and good acceptability in patients who have completed detoxification — the American College of Physicians endorses it as the sole first‑line option. 2
Moderate‑certainty meta‑analysis shows that acamprosate raises the absolute probability of sustained abstinence from ≈ 25 % with placebo to ≈ 38 % (OR 1.86, 95 % CI 1.49‑2.33). 1
Moderate‑certainty data indicate superior acceptability: treatment‑related dropout falls from ≈ 50 % with placebo to ≈ 42 % (OR 0.73, 95 % CI 0.62‑0.86). [1][4]

Standard dose: 666 mg (two 333 mg tablets) taken three times daily for patients weighing ≥ 60 kg. 3
Weight‑adjusted reduction: Reduce total daily dose by one‑third for patients weighing < 60 kg. 3
Renal impairment adjustment: 333 mg three times daily for moderate renal impairment (creatinine clearance 30‑50 mL/min). 3
Treatment duration: Minimum 3‑6 months, extendable up to 12 months based on clinical response. 3

Acamprosate must be started only after successful detoxification and confirmed abstinence; initiating earlier has not shown benefit for achieving abstinence. [2][3]

In patients with liver disease, acamprosate is the preferred and only safe pharmacotherapy because it is not metabolised by the liver and carries no hepatotoxicity risk. [3][5]
Baseline liver function tests (e.g., AST, bilirubin, platelet count) should be obtained before starting therapy. 3

Naltrexone (50 mg once daily) is a second‑line option with weaker evidence; it is primarily recommended for individuals aiming to reduce drinking rather than achieve complete abstinence. 1
Evidence for naltrexone’s ability to maintain abstinence in detoxified patients is of lower quality compared with acamprosate. 4

Severe liver disease or hepatic insufficiency: contraindicated due to documented risk of hepatocellular injury (European Association for the Study of Liver Diseases). 5

Adding naltrexone to acamprosate may improve abstinence rates versus placebo (OR 3.68, 95 % CI 1.50‑9.02), but the supporting evidence is low quality and derived from limited studies. [4][5]

Disulfiram is no longer a first‑line choice because of poor compliance, toxicity concerns, and lack of high‑quality evidence for maintaining abstinence. 1

Optimal outcomes with acamprosate require concurrent comprehensive psychosocial interventions and counseling; medication alone is insufficient. 3